| Q41045405 | A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction. |
| Q44303811 | A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer |
| Q34445648 | Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization |
| Q26751332 | Biomarker development in MET-targeted therapy |
| Q54260230 | Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients. |
| Q90353134 | Clinical significance of MET gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy |
| Q26776190 | Clinical significance of MET in gastric cancer |
| Q61443519 | Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial |
| Q49666927 | Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers |
| Q34685451 | Depletion of C3orf1/TIMMDC1 inhibits migration and proliferation in 95D lung carcinoma cells |
| Q37567109 | Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer |
| Q33769437 | Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors |
| Q26741242 | Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature |
| Q40733626 | FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival |
| Q38527414 | Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. |
| Q26776195 | Gastric cancer: The times they are a-changin' |
| Q36414027 | Gastrointestinal malignancies harbor actionable MET exon 14 deletions |
| Q48601823 | HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma |
| Q55071600 | HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. |
| Q33917507 | HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development |
| Q34456612 | High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer |
| Q89303203 | Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples |
| Q37725411 | IKKε and TBK1 expression in gastric cancer |
| Q53878549 | Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET). |
| Q38205887 | Innovative personalized medicine in gastric cancer: time to move forward |
| Q36140765 | MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC). |
| Q36554574 | MET in gastric cancer--discarding a 10% cutoff rule |
| Q37705824 | MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma |
| Q58731708 | MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases |
| Q38675350 | MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. |
| Q99408661 | Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer |
| Q49888000 | Mechanisms of receptor tyrosine kinase activation in cancer |
| Q35562309 | MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression |
| Q33802125 | MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression |
| Q26765208 | Novel targets in the treatment of advanced gastric cancer: a perspective review |
| Q35562996 | PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor |
| Q35719104 | Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity |
| Q44718464 | Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma |
| Q38493294 | Prognostic and predictive value of MET deregulation in non-small cell lung cancer |
| Q39038837 | Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients |
| Q36303653 | Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. |
| Q47143363 | Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection |
| Q55603677 | Proposed Molecular and miRNA Classification of Gastric Cancer. |
| Q34704781 | Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors |
| Q35626803 | Retracted: MiR-144 Inhibits Uveal Melanoma Cell Proliferation and Invasion by Regulating c-Met Expression |
| Q92382425 | Significant function and research progress of biomarkers in gastric cancer |
| Q44283525 | Study of MET protein levels and MET gene copy number in 72 sinonasal intestinal-type adenocarcinomas |
| Q36471685 | Targeted therapies in gastric cancer and future perspectives. |
| Q38731943 | Targeted therapies in gastric cancer treatment: where we are and where we are going. |
| Q36014215 | Targeting MACC1 by RNA interference inhibits proliferation and invasion of bladder urothelial carcinoma in T24 cells |
| Q44826887 | Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer |
| Q41077332 | The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). |
| Q55069791 | The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer. |
| Q38824065 | The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer |
| Q38210070 | The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey |
| Q37302936 | The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study |
| Q92504675 | Volumetric parameters on 18F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET |
| Q38951772 | Y-box binding protein 1 is correlated with lymph node metastasis in intestinal-type gastric cancer. |
| Q38886375 | miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met |